Skip to main content
Fig. 5 | BMC Musculoskeletal Disorders

Fig. 5

From: Topical co‐administration of zoledronate with recombinant human bone morphogenetic protein-2 can induce and maintain bone formation in the bone marrow environment

Fig. 5

μ-CT evaluation of BV/TV and BMD in retrieved β-TCP implants at 3 and 6 weeks after implantation. The columns and bars represent the means and standard deviations (n = 7), respectively. *: P < 0.05. Statistical differences between groups were determined with the one-way ANOVA and post-hoc Bonferroni test. Note: BV/TV, Bone volume/ Total tissue volume; BMD, Bone mineral density

Back to article page

BMC Musculoskeletal Disorders

ISSN: 1471-2474

Contact us